Tono Y - Search Results

1

Multiple Blood Culture Sampling, Proper Antimicrobial Choice, and Adequate Dose in Definitive Therapy Supported by the Antimicrobial Stewardship Team Could Decrease 30-Day Sepsis Mortality Rates.

Saito N, Tsuchiya J, Itoga M, Okamura Y, Tsuyama H, Kimura M, Inoue F, Kimura T, Ozaki H, Tono Y, Minakawa S, Tomita H. Saito N, et al. Among authors: tono y. Infect Drug Resist. 2024 Jan 22;17:207-219. doi: 10.2147/IDR.S445917. eCollection 2024. Infect Drug Resist. 2024. PMID: 38283110 Free PMC article.

2

Relationship Between Change Rate of Tacrolimus Clearance During Continuous Intravenous Infusion and Recipient Recovery at an Early Stage After Living Donor Liver Transplantation.

Nakagawa J, Ishido K, Tono Y, Kimura N, Wakiya T, Okamura Y, Hakamada K, Niioka T. Nakagawa J, et al. Among authors: tono y. Eur J Drug Metab Pharmacokinet. 2020 Oct;45(5):619-626. doi: 10.1007/s13318-020-00628-2. Eur J Drug Metab Pharmacokinet. 2020. PMID: 32514937

3

Cardiac angiosarcoma with pulmonary and adrenal metastases diagnosed by FDG-PET/CT-guided adrenal biopsy.

Yamashita D, Fujimoto N, Okado R, Ikami A, Yamamoto A, Tono Y, Watanabe K, Hayashi A, Ota S, Mizutani M, Kitamura T, Dohi K. Yamashita D, et al. Among authors: tono y. J Cardiol Cases. 2024 Feb 15;29(6):248-250. doi: 10.1016/j.jccase.2024.02.003. eCollection 2024 Jun. J Cardiol Cases. 2024. PMID: 38826768 Free PMC article.

4

[Interstitial Lung Disease after OK-432 Pleurodesis for Malignant Pleural Effusion in Breast Cancer-A Case Report].

Kobayashi N, Tono Y, Tsunoda A, Oka H, Saito K, Yamashita Y, Mizuno T, Tawara I. Kobayashi N, et al. Among authors: tono y. Gan To Kagaku Ryoho. 2023 Feb;50(2):183-186. Gan To Kagaku Ryoho. 2023. PMID: 36807167 Review. Japanese.

5

Combined use of pathological and genomic alteration analyses for the diagnosis of gray zone lymphoma.

Nishimura K, Miyazaki K, Suzuki K, Hachiya K, Tono Y, Tamaru S, Imai H, Miyoshi H, Ohshima K, Okugawa Y, Tawara I, Yamaguchi M. Nishimura K, et al. Among authors: tono y. J Clin Exp Hematop. 2022;62(4):253-257. doi: 10.3960/jslrt.22024. J Clin Exp Hematop. 2022. PMID: 36575002 Free PMC article.

6

SMARCA2/BRM-Deficient Undifferentiated/Rhabdoid Carcinoma of Unknown Primary Site.

Tono Y, Sukeno K, Tsunoda A, Saito K, Yamashita Y, Usui M, Uchida K, Imai H, Mizuno T, Tawara I. Tono Y, et al. Case Rep Oncol. 2022 Mar 3;15(1):163-169. doi: 10.1159/000521632. eCollection 2022 Jan-Apr. Case Rep Oncol. 2022. PMID: 35431870 Free PMC article.

7

Atezolizumab-Induced Sarcoidosis-Like Reaction in a Patient with Metastatic Breast Cancer.

Tsunoda A, Mizuno T, Iida S, Uchida K, Yamashita M, Sukeno K, Oka H, Tono Y, Ishihara M, Saito K, Tamaru S, Yamanaka K, Tawara I. Tsunoda A, et al. Among authors: tono y. Case Rep Oncol Med. 2022 Jan 27;2022:2709062. doi: 10.1155/2022/2709062. eCollection 2022. Case Rep Oncol Med. 2022. PMID: 35127188 Free PMC article.

8

CD204-positive macrophages accumulate in breast cancer tumors with high levels of infiltrating lymphocytes and programmed death ligand-1 expression.

Nagano M, Saito K, Kozuka Y, Ichishi M, Yuasa H, Noro A, Imai N, Shibusawa M, Kimoto M, Ishitobi M, Tono Y, Oda H, Ishihara M, Mizuno T, Ogawa T, Katayama N. Nagano M, et al. Among authors: tono y. Oncol Lett. 2021 Jan;21(1):36. doi: 10.3892/ol.2020.12297. Epub 2020 Nov 12. Oncol Lett. 2021. PMID: 33262828 Free PMC article.

9

First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors.

Ishihara M, Tono Y, Miyahara Y, Muraoka D, Harada N, Kageyama S, Sasaki T, Hori Y, Soga N, Uchida K, Shiraishi T, Sato E, Kanda H, Mizuno T, Webster GA, Ikeda H, Katayama N, Sugimura Y, Shiku H. Ishihara M, et al. Among authors: tono y. Cancer Immunol Immunother. 2020 Apr;69(4):663-675. doi: 10.1007/s00262-020-02483-1. Epub 2020 Jan 24. Cancer Immunol Immunother. 2020. PMID: 31980914 Free PMC article. Clinical Trial.

10

Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers.

Tono Y, Ishihara M, Miyahara Y, Tamaru S, Oda H, Yamashita Y, Tawara I, Ikeda H, Shiku H, Mizuno T, Katayama N. Tono Y, et al. Oncotarget. 2018 Feb 16;9(19):14909-14921. doi: 10.18632/oncotarget.24504. eCollection 2018 Mar 13. Oncotarget. 2018. PMID: 29599915 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

20 results

Search Page